Long-Term Safety, Tolerability and Survival in Patients with Pulmonary Arterial Hypertension Treated with Macitentan: Results from the SERAPHIN Open-Label Extension
暂无分享,去创建一个
A. Torbicki | G. Simonneau | O. Sitbon | L. Rubin | T. Pulido | M. Delcroix | N. Galiè | S. Mehta | R. Channick | P. Jansa | B. Sastry | R. Souza | L. Chamitava | N. Boyanova | C. Stein
[1] O. Sitbon,et al. Long-Term Survival, Safety and Tolerability with Selexipag in Patients with Pulmonary Arterial Hypertension: Results from GRIPHON and its Open-Label Extension , 2021, Advances in Therapy.
[2] Y. Rao,et al. Follow-Up Functional Class and 6-Minute Walk Distance Identify Long-Term Survival in Pulmonary Arterial Hypertension , 2020, Lung.
[3] V. Sintchenko,et al. Nontuberculosis mycobacteria infections: would there be pharmacodynamics without pharmacokinetics? , 2019, European Respiratory Journal.
[4] V. Cottin,et al. INITIAL TREATMENT COMBINATION WITH MACITENTAN AND TADALAFIL IN PATIENTS WITH PULMONARY ARTERIAL HYPERTENSION: RESULTS FROM THE OPTIMA STUDY , 2019, Chest.
[5] V. McLaughlin,et al. Macitentan in pulmonary hypertension (PH): Data from OPUS and OrPHeUS real-world data sets , 2019, Pulmonary hypertension.
[6] P. De Groote,et al. Macitentan for the treatment of portopulmonary hypertension (PORTICO): a multicentre, randomised, double-blind, placebo-controlled, phase 4 trial. , 2019, The Lancet. Respiratory medicine.
[7] M. Gatzoulis,et al. Evaluation of Macitentan in Patients With Eisenmenger Syndrome , 2018, Circulation.
[8] Z. Jing,et al. Macitentan for the treatment of inoperable chronic thromboembolic pulmonary hypertension (MERIT-1): results from the multicentre, phase 2, randomised, double-blind, placebo-controlled study. , 2017, The Lancet. Respiratory medicine.
[9] S. Rosenkranz,et al. Mortality in pulmonary arterial hypertension: prediction by the 2015 European pulmonary hypertension guidelines risk stratification model , 2017, European Respiratory Journal.
[10] M. Humbert,et al. Predictors of long-term outcomes in patients treated with riociguat for pulmonary arterial hypertension: data from the PATENT-2 open-label, randomised, long-term extension trial. , 2016, The Lancet. Respiratory medicine.
[11] R. Benza,et al. Five-Year outcomes of patients enrolled in the REVEAL Registry. , 2015, Chest.
[12] T. Fleming,et al. Long-term sildenafil added to intravenous epoprostenol in patients with pulmonary arterial hypertension. , 2014, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.
[13] R. Barst,et al. From Short-Term Benefits to Long-Term Outcomes: The Evolution of Clinical Trials in Pulmonary Arterial Hypertension , 2013, Pulmonary circulation.
[14] Z. Jing,et al. Macitentan and morbidity and mortality in pulmonary arterial hypertension. , 2013, The New England journal of medicine.
[15] R. Benza,et al. An evaluation of long-term survival from time of diagnosis in pulmonary arterial hypertension from the REVEAL Registry. , 2012, Chest.
[16] H. Farber. Validation of the 6-minute walk in patients with pulmonary arterial hypertension: trying to fit a square PEG into a round hole? , 2012, Circulation.
[17] W. Seeger,et al. Long-term effects of inhaled treprostinil in patients with pulmonary arterial hypertension: the Treprostinil Sodium Inhalation Used in the Management of Pulmonary Arterial Hypertension (TRIUMPH) study open-label extension. , 2011, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.
[18] T. Fleming,et al. Long-term treatment with sildenafil citrate in pulmonary arterial hypertension: the SUPER-2 study. , 2011, Chest.
[19] T G Clark,et al. Survival Analysis Part I: Basic concepts and first analyses , 2003, British Journal of Cancer.
[20] Douglas G Altman,et al. Survival plots of time-to-event outcomes in clinical trials: good practice and pitfalls , 2002, The Lancet.